Cytopénies auto-immunes associées au lymphome de Hodgkin : étude rétrospective monocentrique

Caré, Weniko; Arnautou, P.; Segot, Amandine; Charry, F. de; Foissaud, Vincent; Bugier, Sarah; Cournac, J.M.; Konopacki, Johanna; Malfuson, Jean-Valère

doi:10.1016/j.revmed.2019.03.328

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AIHA is best characterized in chronic lymphocytic leukemia (CLL), but is found as a complication in many lymphoma entities and in solid tumors. 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 Severe AIHA may lead to initiation of antilymphoma treatment, but in many cases, immunosuppression stabilizes the condition for further watchful waiting ( Figure 1A-C ). The International Workshop on Chronic Lymphocytic Leukemia Guidelines, for instance, explicitly state that AICs mimicking a CLL Binet C stage can be treated with immunosuppressive therapy.…”

Section: Aihamentioning

confidence: 99%

How I manage autoimmune cytopenias in patients with lymphoid cancer

Porpaczy¹,

Jaeger

2022

Blood

View full text Add to dashboard Cite

Autoimmune conditions can occur at any temporary relationship with malignant lymphomas. In many instances, treatment at diagnosis is not required, but symptomatic autoimmune conditions represent an indication for treatment particularly in chronic lymphoproliferative diseases. Treatment is selected depending on the predominant condition - autoimmune disease (immunosuppression) or lymphoma (anti-lymphoma therapy). Steroids as well as anti-CD20 antibodies are effective against both and may suppress the autoimmune complication for a prolonged period. Efficacy of B-cell receptor inhibitors has provided us with novel insights into the pathophysiology of antibody-producing B-cells. Screening for underlying autoimmune conditions is part of the lymphoma work-up since other drugs like immunomodulators or checkpoint inhibitors should be avoided or used with caution. Here we discuss diagnostic challenges and treatment approaches for different situations involving lymphomas and autoimmune cytopenias.

show abstract